Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Chemotherapy

NCT07669506 is registered in ClinicalTrials.gov with Natureceuticals Sdn Bhd as lead sponsor.

NCT NCT07669506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07669506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing Chemotherapy
Lead sponsor
Natureceuticals Sdn Bhd
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2025
Completion date
June 15, 2026
Enrollment
180 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, chemotherapy, adjuvant, fatigue, quality of life